Improve quadruple aim strategies with a hereditary cancer risk assessment program

Up to 10% of all cancers are caused by inherited genetic mutations, but traditional screening approaches may miss more than 30% of eligible individuals.1,2 Myriad supports your health system goals with a robust, fully supported hereditary cancer risk assessment program that is designed to help you systematically identify, evaluate, and manage your at-risk patients, without adding complexity to your workflow or unnecessary burden to your staff. Medical management changes for the 53% of patients who qualify after MyRisk® testing3 may include important services such as enhanced imaging, specialist consultations, cancer screenings, and other risk reduction interventions that deliver improved outcomes and service-line utilization.

Executive Brief
The Unmet Opportunity in Hereditary Cancer Risk Assessment
Read now

ENHANCE CLINICAL EFFICACY

>1 in 4 patients may meet guidelines for hereditary cancer genetic testing.2 Here’s how to identify and care for them.

Pre-appointment electronic screening

Identify more high-risk patients with pre-appointment digital screening and genetic testing during regularly scheduled appointments.

Integrated digital education and genetic counselors

Offer on demand, no cost personalized education to help patients see the value in testing at the point of care.

Proven genetic test with more than 30 years of data

The MyRisk® test accurately identifies high-risk patients that may be eligible for risk-reduction services such as: specialist consults, enhanced imaging, cancer screening, and prophylactic surgeries.

Infographic
7 ways a hereditary cancer risk assessment program can identify more women for precision care
Read now

Video
Clinicians on Programmatic Hereditary Cancer Risk Assessment
Watch

Beyond the test – how Myriad supports hereditary cancer risk assessment programs

Myriad provides beginning to end program support to help health systems like yours develop program workflows, provide ongoing staff training, educate patients before and after the test, integrate screening and ordering within your EMR, and streamline patient payment details.

  • Pre-visit screener in patient portalDigital screening with MyGeneHistory® based on medical society guidelines

  • Pre-test genetic educationPatient education materials are provided along with access to a board-certified genetic counselor

  • Simple MyRisk® test orderingOnline portal and RIS/EMR integration

  • AffordabilityMost eligible patients pay $0 out of pocket4, and financial assistance may be available for those that qualify

  • Actionable
    results
    Easy to use MyRisk® Management Tool and personalized 5-year and lifetime breast cancer RiskScore® for eligible patients

  • Post-test genetic consultsBoard-certified genetic counselors available M-F for individualized results support for patients and providers

  • Care management plan developmentClear guideline-based management recommendations to help with circle of care referrals

Streamline CLINICAL WORKFLOWS

Improve patient experience and operational efficiency

Work with Myriad to implement a scalable hereditary cancer risk assessment program that identifies and manages high-risk patients and their close relatives across your system. With our EMR integrated digital tools, expert support, and proven implementation success, you can deliver more efficient, guideline-based care, while improving patient health outcomes and operational performance.5

Articles
Modernizing Genetic Counseling in Women’s Health Programs: Enhancing Clinical Workflows While Reducing Provider Burden
Read now

The Clinical Impact of Myriad’s Hereditary Cancer Genetic Testing and Prenatal Screening
Read now

Schedule a hereditary cancer risk assessment conversation today

Together, we can implement a program that works in your health system — and supports your commitment to the best care.

By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.


Hidden Fields









case study

Learn how one major health system interrupted cancer

A multi-state health system’s hereditary cancer risk assessment program began with one clinician recognizing an opportunity to improve patients’ lives and the quality of care at her clinic. It became the framework for identifying and treating the women in their care who are at high-risk for hereditary cancer. Read how they did it.

Quote icon

“Affecting communities at the population health level can make lasting changes for generations to come. Moving away from a one-size-fits-all approach to cancer risk assessment and management improves quality of care and patient satisfaction.”

An OB/GYN at a multi-state health system

Real-world case study: Reducing hereditary cancer risk at scale5

breast icon

86,640

patients screened

breast icon

25,504

eligible for genetic testing

breast icon

11,411

tests reported

breast icon

7,236

eligible for breast MRI (TCv8)

breast icon

1,046

pathogenic mutations found

breast icon

43,817

medical procedures selected for 6,369 patients

View full case study
breast icon

43,817

medical procedures selected for 6,369 patients

Costs are lower when you catch cancer earlier

Health systems need to reduce the cost of healthcare without sacrificing quality. A programmatic approach to women’s hereditary cancer risk assessment can help.

$72k

spent on breast cancer care in the first two years following early-stage diagnosis6

vs.

$182k

spent on breast cancer care in first two years following late-stage diagnosis6

Costs are lower when you catch cancer earlier

Health systems need to reduce the cost of healthcare without sacrificing quality. A programmatic approach to women’s hereditary cancer risk assessment can help.

Learn more about how genetic insights can improve population health and system utilization

You may find these resources helpful as you research genetic testing for your health system.

0
Executive Briefing

The unmet opportunity in hereditary
cancer risk assessment

Expanding access, improving outcomes, and enhancing utilization.

0
Case Study

Cancer, Interrupted – How one health system worked with Myriad to counter hereditary cancer

According to a review of public data, 36% of Americans have at least one first-degree relative with cancer. Yet, a 2022 Myriad survey revealed that 30% of women don’t know whether their family has a history of cancer.

0
Article

The Clinical Impact of Myriad Women’s Health on Hereditary Cancer Risk Assessment and Genetic Testing

Genetic tests aren’t all the same. Learn why you need to consider accuracy, scientific rigor, and service offerings when deciding on which tests to use.

0
Article

5 Ways a Women’s Genetic Testing Provider Should Align with Your Value-Based Care Goals

Genetic testing isn’t just about the results. Risk assessment, education, and counseling are also required. Learn how to identify testing labs that align with your value-based care goals.

  1. MD Anderson Cancer Center. Is cancer hereditary? MD Anderson Cancerwise. Published October 21, 2025. Accessed April 21, 2026. https://www.mdanderson.org/cancerwise/is-cancer-hereditary.h00-159780390.htm
  2. Waldman, R, DeFrancesco, M, Feltz, J, et al. FACS. Online Screening and Virtual Patient Education for Hereditary Cancer Risk Assessment and Testing. Obstetrics & Gynecology. 145(2):p 177-185, February 2025
  3. Myriad internal data based on the MyRisk tests reported between September 1, 2021 and February 1, 2023, ordered for unaffected patients by OB/GYN and Primary Care healthcare providers.
  4. Based on a review of 12 months of past claim data for major insurance carriers across the US, the majority of patients face no out-ofpocket costs for their MyRisk test. Last updated 2025.
  5. Myriad Genetics. Cancer, Interrupted. Published August 2025. Accessed May 18, 2026. https://myriad.com/womens-health/wp-content/uploads/sites/10/2025/08/MyRisk-HCPHCRA-Case-Study-Booklet.pdf
  6. Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23–32. https://pmc.ncbi.nlm.nih.gov/articles/
PMC4822976/
Schedule a strategy session